Pre-COVID, the traditional sales rep model, although still dominant, was losing momentum amid tighter regulatory scrutiny and doctor disengagement. During the pandemic, pharma has had to pivot overnight to virtual rep visits, and place increased focus and investment on other digital channels to maintain engagement.
As the world continues to open up, what model should pharma expect post-pandemic – a return to the traditional approach or some sort of hybrid model, taking the best of in-person and digital engagement? And with retail and tech giants setting an expectation amongst consumers for a seamless and integrated experience across multiple channels, can pharma deliver a similar sophisticated omnichannel experience to its customers?
Key takeaways:
Watch this webcast in which research experts, Colin Tan and Callum McCulloch , explore the impact of COVID on the changing digital behaviors of healthcare stakeholders, and considers what impact this is having on evolving omnichannel marketing strategy. They will also demonstrate how market research can highlight important differences in customers’ channel needs and preferences. Finally, they will introduce us to the new breed of online influencers – physicians and specialists with a huge following and the power to educate and influence the medical community. Demonstrating how to profile, map and engage with these physicians so that pharma can guide the online conversation in channels where they have less control.
Jump to a slide with the slide dots.
Globally, the population is aging rapidly with an increased life expectancy due to improved health, better living conditions and lower birth rates.
Read moreFind out about our team of emerging market experts with this infographic outlining our experience and expertise across a vast number of regions.
Read moreRapport is our monthly newsletter where we share our latest expertise and experience.